Dyadic International (DYAI) Net Shares Issued and Repurchased (2019 - 2026)
Dyadic International's (DYAI) quarterly Net Shares Issued and Repurchased came in at $516250.0 in Q1 2026, down 23.35% year-over-year from $673500.0 in Q1 2025, and down 42.12% quarter-over-quarter from $891875.0 in Q4 2025.
Analysis
Dyadic International (DYAI) Net Shares Issued and Repurchased (2019 - 2026) Analysis & Trends
Dyadic International has disclosed Net Shares Issued and Repurchased across 8 years of filings, most recently posting $516250.0 for Q1 2026.
- In Q1 2026, Net Shares Issued and Repurchased fell 23.35% year-over-year to $516250.0; the TTM figure through Mar 2026 stood at $516250.0 (down 23.35% YoY), while the FY2025 annual figure was $891875.0, up 7.36% from the prior year.
- Net Shares Issued and Repurchased came in at $516250.0 for Q1 2026 at Dyadic International, down from $891875.0 in the prior quarter.
- In the past five years, Net Shares Issued and Repurchased ranged from a high of $891875.0 in Q4 2025 to a low of $75000.0 in Q1 2022.
- Average Net Shares Issued and Repurchased over 5 years is $682108.3, with a median of $772600.0 recorded in 2024.
- Year-over-year, Net Shares Issued and Repurchased plunged 89.94% in 2022 and surged 843.8% in 2023.
- Over 5 years, Net Shares Issued and Repurchased stood at $865825.0 in 2022, then declined by 6.98% to $805350.0 in 2023, then advanced by 3.15% to $830725.0 in 2024, then gained by 7.36% to $891875.0 in 2025, then plunged by 42.12% to $516250.0 in 2026.
- Per Business Quant data, the three most recent Net Shares Issued and Repurchased figures were $516250.0 in Q1 2026, $891875.0 in Q4 2025, and $673500.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - | 516,250.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 516,250.00 |
| Dec 31, 2025 | 891,875.00 |
| Mar 31, 2025 | 673,500.00 |
| Dec 31, 2024 | 830,725.00 |
| Mar 31, 2024 | 772,600.00 |
| Dec 31, 2023 | 805,350.00 |
| Mar 31, 2023 | 707,850.00 |
| Dec 31, 2022 | 865,825.00 |
| Mar 31, 2022 | 75,000.00 |
| Dec 31, 2021 | 870,825.00 |
| Mar 31, 2021 | 745,825.00 |
| Dec 31, 2020 | 913,000.00 |
| Dec 31, 2019 | 1.09 Mn |